Chemo-Immunotherapy: Observational Trial of Carboplatin-pegylated Liposomal Doxorubicin (PLD) or Doxorubicin Combination Chemotherapy With Tocilizumab, a Humanized Monoclonal Antibody Against the Human Interleukin-6 (IL-6) Receptor, and Pegylated Interferon Alpha (Peg-Intron) for Patients With Recurrent Ovarian Cancer.

Trial Profile

Chemo-Immunotherapy: Observational Trial of Carboplatin-pegylated Liposomal Doxorubicin (PLD) or Doxorubicin Combination Chemotherapy With Tocilizumab, a Humanized Monoclonal Antibody Against the Human Interleukin-6 (IL-6) Receptor, and Pegylated Interferon Alpha (Peg-Intron) for Patients With Recurrent Ovarian Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Tocilizumab (Primary) ; Carboplatin; Doxorubicin; Doxorubicin liposomal; Peginterferon alfa-2b
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PITCH
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jul 2015 Results published in the Annals of Oncology.
    • 23 Jan 2014 Planned End Date changed from 1 Sep 2014 to 1 Sep 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top